Abstract
BackgroundClinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. However, the responsiveness of MMRD cancers to αPD-1 therapy...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have